BRIEF—Jiangsu Hengrui Pharma launches Luzsana Biotechnology
18 May 2022
Jiangsu Hengrui Pharmaceuticals – one of the largest pharma companies in China – today announced it is launching Luzsana Biotechnology.
What makes Luzsana unique, says Hengrui, is that:
- Luzsana, a wholly-owned subsidiary of Hengrui Pharma, will co-develop medicines with Hengrui Pharma and commercialize in the USA, Europe and Japan;
- Initial pipeline focuses on 11 high-potential programs in oncology, oncology supportive care, and metabolics, across all stages of development; and
- Luzsana can leverage Hengrui Pharma’s discovery work, clinical trials network and manufacturing capabilities to reduce cost savings and reinvest money in tailored solutions that will help improve availability, accessibility, and affordability of medicines.
More on this story...
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze